Recent reports indicate that inhibiting the RhoA/ROCK1/LIMK1 pathway, which is involved in the CD276-dependent regulation of the actin cytoskeleton, can reverse the effects of B7-H3 overexpression on the aggressive phenotype of CRC cells [93]. This evidence concerns the gene LIMK1 and colorectal carcinoma.